|
시장보고서
상품코드
2051168
신경통 치료 시장 : 약제 유형별, 투여 경로별, 중증도별, 판매채널별, 지역별Neuralgia Treatment Market, By Drug Type, By Route of Administration, By Severity, By Distribution Channel, By Geography |
||||||
신경통 치료 시장은 2026년에 27억 달러로 추정되고, 2033년까지 43억 5,000만 달러에 이를 것으로 예상되고 있습니다. 또한 2026-2033년 CAGR 6.8%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 2026년 시장 규모 : | 27억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 6.80% | 2033년 시장 규모 예측 : | 43억 5,000만 달러 |
신경통(신경병증성 통증이라고도 함)은 체성 감각신경계에 영향을 미치는 손상이나 질환으로 인해 발생하는 만성 통증입니다. 그 특징은 극심한 통증, 찌르는 듯한 통증, 날카로운 통증이며, 그 통증은 과도하게 느껴지거나 예측할 수 없는 통증입니다. 신경통의 일반적인 유형으로는 3차신경통, 대상포진으로 인한 대상포진 후 신경통, 섬유근육통 등이 있습니다. 세계 신경통 치료제 시장은 신경병성 통증 질환의 유병률 증가와 이 질환에 취약한 고령 인구 증가로 인해 최근 몇 년 동안 지속적으로 성장하고 있습니다. 또한, 효능이 향상되고 부작용을 최소화한 신약 개발도 신경통 치료에 대한 수요를 촉진하고 있습니다.
시장 역학:
세계 신경통 치료제 시장은 신경병성 통증 질환의 유병률 증가와 전 세계 고령화 진행에 의해 주도되고 있습니다. 신경병증성 통증은 노화에 따른 신경계의 퇴행성 변화로 인해 노인들에게 많이 나타납니다. 또한, 기존 치료법에 비해 효능이 우수하고 안전성 프로파일이 우수한 신약 개발도 시장 성장을 견인하고 있습니다. 카르바마제핀과 가바펜틴은 신경통 치료에 일반적으로 사용되는 특허가 만료된 약물입니다. 그러나 이들 약제에는 내약성 문제가 있어 복약 순응도를 떨어뜨리는 원인이 되고 있습니다. 이에 따라 위험-편익비가 개선된 나트륨 채널 차단제, NMDA 수용체 길항제, α-2δ 리간드 등 새로운 치료제 계열의 연구 개발이 진행되고 있습니다. 한편, 질병 변형 치료법의 부족과 새로운 치료법의 높은 비용은 시장 확대를 어느 정도 억제하는 요인으로 작용하고 있습니다. 그럼에도 불구하고, 통증 관리에 대한 인식 증가와 브랜드 의약품의 제네릭 의약품의 가용성은 향후 몇 년 동안 신경통 치료 시장의 기업들에게 큰 기회를 창출할 것입니다.
본 조사의 주요 특징:
세계의 신경통 치료 시장에 대한 상세한 분석을 제공하며, 2025년을 기준 연도, 예측 기간(2026-2033년) 시장 규모(10억 달러)와 CAGR(%)을 조사하여 예측한 보고서입니다.
이 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
이 보고서는 다음과 같은 매개 변수를 기반으로 세계 신경통 치료제 시장의 주요 기업 프로파일을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
이 조사에서 다루는 주요 기업으로는 글락소 스미스 클라인(GlaxoSmithKline PLC), 화이자(Pfizer Inc.), 노바티스(Novartis AG), 바이오젠(Biogen), 카디라 헬스케어(Kadira Healthcare Ltd.), 테바 제약산업(Teva Pharmaceutical Industries Ltd.), 사노피(Sanofi S.A.), 암젠(Amgen), Lundbeck Pharmaceuticals, Inc. Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen, Eli Lilly & Company, Astellas Pharmaceuticals, Johnson & Johnson, Merck & Company, AbbVie, H. Lundbeck & Co. 및 H. 룬드벡 A/S 등이 포함됩니다.
이 보고서는 각 기업의 마케팅 담당자와 경영진이 향후 제품 출시, 제품 개선, 시장 확대 및 마케팅 전략과 관련하여 정보에 입각한 의사결정을 내릴 수 있도록 도와줄 것입니다.
이 세계 신경통 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 세계 신경통 치료제 시장을 분석하는 데 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 신경통 치료 시장 : 약제 유형별, 2021년-2033년
제5장 세계의 신경통 치료 시장 : 투여 경로별, 2021년-2033년
제6장 세계의 신경통 치료 시장 : 중증도별, 2021년-2033년
제7장 세계의 신경통 치료 시장 : 유통 채널별, 2021년-2033년
제8장 세계의 신경통 치료 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고 문헌 및 조사 방법
LSH 26.06.17Neuralgia Treatment Market is estimated to be valued at USD 2.70 Bn in 2026 and is expected to reach USD 4.35 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.70 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.80% | 2033 Value Projection: | USD 4.35 Bn |
Neuralgia, also known as neuropathic pain, is a chronic pain caused by damage or disease affecting the somatosensory nervous system. It is characterized by shooting, stabbing, and sharp pain that feels exaggerated or unpredictable. Some common types of neuralgia include trigeminal neuralgia, postherpetic neuralgia caused by shingles, and fibromyalgia. The global neuralgia treatment market has been witnessing growth in recent times owing to the rising prevalence of neuropathic pain disorders and growing geriatric population who are more prone to such conditions. Furthermore, the development of novel drugs providing improved efficacy and minimal side effects are also fueling the demand for neuralgia treatments.
Market Dynamics:
The global neuralgia treatment market is driven by the increasing incidence of neuropathic pain disorders coupled with the growing geriatric population globally. Neuropathic pain conditions are more prevalent in the elderly due to age-related degenerative changes in the nervous system. Additionally, the market growth is facilitated by the development of newer drugs offering enhanced efficacy and favorable safety profiles over conventional treatment options. Carbamazepine and gabapentin are off-patent drugs commonly used to treat neuralgia. However, their tolerability issues lead to poor compliance. This has triggered R&D of novel therapeutic classes like sodium channel blockers, NMDA receptor antagonists, and alpha-2 delta ligands that demonstrate improved risk-benefit ratios. On the other hand, lack of disease-modifying treatments and high cost of newer therapies are some challenges restraining the market expansion to a certain extent. Nevertheless, rise in awareness about pain management and availability of generic versions of branded drugs create huge opportunities for the neuralgia treatment market players in the coming years.
Key Features of the Study:
This report provides in-depth analysis of the global neuralgia treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global neuralgia treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline PLC, Pfizer Inc., Novartis AG, Biogen, Cadila Healthcare Limited, Lundbeck Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Amgen Inc., Eli Lilly and Company, Astellas Pharma Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and H. Lundbeck A/S.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global neuralgia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuralgia treatment market
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Anticonvulsants
- Antidepressants
- Opioids
- Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Others
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous
- Transdermal
- Others
- Severity Insights (Revenue, USD Bn, 2021 - 2033)
- Mild
- Moderate
- Severe
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- GlaxoSmithKline PLC
- Pfizer Inc.
- Novartis AG
- Biogen
- Cadila Healthcare Limited
- Lundbeck Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- Amgen Inc.
- Eli Lilly and Company
- Astellas Pharma Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- AbbVie Inc.
- Lundbeck A/S
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neuralgia Treatment Market, By Drug Type
- Global Neuralgia Treatment Market, By Route of Administration
- Global Neuralgia Treatment Market, By Severity
- Global Neuralgia Treatment Market, By Distribution Channel
- Global Neuralgia Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Neuralgia Treatment Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Anticonvulsants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Opioids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Non-steroidal anti-inflammatory Drugs (NSAIDs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Neuralgia Treatment Market, By Route of Administration, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Neuralgia Treatment Market, By Severity, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Mild
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Moderate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Severe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Neuralgia Treatment Market, By Distribution Channel, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Neuralgia Treatment Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Severity, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Biogen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cadila Healthcare Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck Pharmaceuticals LLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck A/S
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
